Hancock Whitney Corp Sells 534 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Hancock Whitney Corp trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,323 shares of the medical equipment provider’s stock after selling 534 shares during the period. Intuitive Surgical accounts for approximately 0.8% of Hancock Whitney Corp’s holdings, making the stock its 26th largest position. Hancock Whitney Corp’s holdings in Intuitive Surgical were worth $23,721,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after acquiring an additional 493,126 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Intuitive Surgical by 1.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after purchasing an additional 272,741 shares during the last quarter. Capital World Investors raised its position in shares of Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after purchasing an additional 73,634 shares during the period. Edgewood Management LLC lifted its stake in shares of Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after buying an additional 374,667 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in shares of Intuitive Surgical by 4.6% during the 1st quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock worth $1,791,253,000 after buying an additional 198,483 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $486.20 on Friday. The company has a 50-day moving average of $468.01 and a 200-day moving average of $424.86. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $496.18. The company has a market capitalization of $172.46 billion, a price-to-earnings ratio of 87.76, a PEG ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.18 earnings per share. Sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ISRG. BTIG Research lifted their target price on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Robert W. Baird lifted their price objective on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Citigroup boosted their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Evercore ISI lowered their target price on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a report on Friday, July 19th. Finally, Piper Sandler upped their price target on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $446.45.

Insider Buying and Selling

In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the transaction, the insider now directly owns 295 shares of the company’s stock, valued at $145,113.45. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the sale, the insider now directly owns 295 shares of the company’s stock, valued at $145,113.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock worth $25,528,753 in the last 90 days. 0.90% of the stock is owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.